Rexahn Pharmaceuticals, Inc., a development stage biopharmaceutical company, engages in the discovery and development of treatments for cancer and other disorders of central nervous system. The company s product candidates include Archexin that is in Phase II clinical trials for the treatment of renal cell carcinoma, glioblastoma, ovarian cancer, stomach cancer, and pancreatic cancer; Serdaxin, which has completed Phase IIb clinical trial for the treatment of depression and Parkinson s disease; and Zoraxel that has completed Phase IIa clinical trials for the treatment of for sexual dysfunction through modulating the sexual activity control center in the brain. Its pre-clinical product pipeline comprises RX-1792, a small molecule anticancer epidermal growth factor receptor inhibitor; RX-5902, small molecule anticancer RNA helicase regulator; RX-3117, a small molecule anticancer DNA synthesis inhibitor to treat cancer cells; RX-8243, a small molecule anticancer aurora kinase inhibitor; RX-0201-Nano, a nanoliposomal anticancer Akt inhibitor; RX-0047-Nano, a nanoliposomal anticancer HIF-1 alpha inhibitor; and RX-21101, a nanopolymer anticancer drug. The company has various collaborative research and development relationships with universities, research institutions, and other organizations, including Teva Pharmaceutical Industries; TheraTarget, Inc.; Korea Research Institute of Chemical Technology; The University of Maryland Baltimore; Revaax Pharmaceuticals LLC; and Rexgene Biotech Co., Ltd. Rexahn Pharmaceuticals, Inc. was founded in 2001 and is based in Rockville, Maryland.
Symbol:
Current Quote
last: 0.39
bid:
ask:
volume: 4055512

as of (GMT): 2013-05-22 15:59:00
*Quotes delayed by 20min.
Stock Exchange / Market : AMEX
 Off list - 206 consecutive market days. Off list as of 08/29/2008 through 05/21/2013 

3 Month
RNN 3 Month

6 Month
RNN 6 Month

1 Year
RNN 1 Year

Borrow Rates (per share)